Hartaj Singh
Stock Analyst at Oppenheimer
(1.69)
# 3,457
Out of 5,131 analysts
108
Total ratings
45%
Success rate
-7.95%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $21.14 | +75.02% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $768.00 | +17.19% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $122.60 | +1.96% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $460.59 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $77.80 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $12.72 | +120.13% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $482.39 | +24.38% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $33.84 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $4.26 | +134.74% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.46 | +4,009.59% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $2.14 | +320.56% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $1.54 | +2,497.40% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $9.97 | +120.66% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $4.11 | +15,715.09% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $17.04 | +76.06% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $21.14
Upside: +75.02%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $768.00
Upside: +17.19%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $122.60
Upside: +1.96%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $460.59
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $77.80
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $12.72
Upside: +120.13%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $482.39
Upside: +24.38%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $33.84
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $4.26
Upside: +134.74%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.46
Upside: +4,009.59%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.14
Upside: +320.56%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $1.54
Upside: +2,497.40%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $9.97
Upside: +120.66%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $4.11
Upside: +15,715.09%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $17.04
Upside: +76.06%